Çabuk and Hazır [48] examined the impact of SGLT2 inhibitors (empagliflozin or dapagliflozin) for at least 6 months on the development of CAN in patients with type II diabetes undergoing CAG or PCI. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.